Besifovir and tenofovir exalidex look promising as new hepatitis B drugs
Triple combination cures most hepatitis C patients with prior DAA treatment failure
EASL releases updated hepatitis B guidelines at International Liver Congress
Switching to TAF for hepatitis B improves kidney function and bone loss
Generic hepatitis C drugs continue to produce high cure rates
AbbVie combination cures 95% of genotype 3 hepatitis C
New AbbVie hepatitis C combination cures 99% of people with cirrhosis
Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
